Literature DB >> 12175100

Down regulation of glucocorticoid receptors in early-diagnosed rheumatoid arthritis.

A A van Everdingen1, A M Huisman, M J G Wenting, Siewertsz van Reesema, J W G Jacobs, J W J Bijlsma.   

Abstract

OBJECTIVE: In patients with rheumatoid arthritis (RA) of longer duration, glucocorticoid receptor (GR) down-regulation has been reported without any change in cortisol levels. This phenomenon might play a role in the aetio-pathogenesis of RA. Therefore we studied GR expression, as well as the serum cortisol levels, in patients with recently diagnosed RA.
METHODS: In 81 early diagnosed RA patients with disease duration < 1 year (52F/29M; mean (SD) age 63 (13) years) and in 39 age and sex matched controls (23F/16M; mean age 63 (15) years) blood samples were taken between 8-10 h AM. GR expression (GR-number and GR-affinity), serum cortisol levels, ESR, CRP, painful and swollen joints were measured.
RESULTS: A significantly lower GR-number was found in the female patients compared with female controls: 7.0 versus 9.8fmol/million cells, respectively (difference: 2.8, 95% CI 1.1 - 4.6). Interestingly, also serum cortisol levels were significantly lower in the female patients compared with the female controls: 0.21 versus 0.41 micromol/l, respectively (difference: 0.20, 95% CI 0.12 - 0.28). However, between the male patients and male controls no difference was found in GR expression nor in serum cortisol levels. Neither in female nor in male patients were correlations found between GR expression and parameters of disease activity nor was there a relation between GR expression and serum cortisol levels.
CONCLUSIONS: Changes in GR expression as well as serum cortisol were not a general phenomenon in early diagnosed RA patients, being present only in females and not related to disease activity. Therefore it seems unlikely that GR expression per se is causally involved in the pathogenesis of RA. We cannot preclude that it may be involved in the incidence, severity and course of RA, as this may be differentially regulated in males and females.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175100

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

2.  Hypermethylation of glucocorticoid receptor gene promoter results in glucocorticoid receptor gene low expression in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.

Authors:  Hongbo Chen; Junfen Fan; Qiyang Shou; Lizong Zhang; Hongzhen Ma; Yongsheng Fan
Journal:  Rheumatol Int       Date:  2015-04-22       Impact factor: 2.631

Review 3.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

4.  Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue.

Authors:  Mary C Davis; Alex J Zautra; Jarred Younger; Sarosh J Motivala; Jeanne Attrep; Michael R Irwin
Journal:  Brain Behav Immun       Date:  2007-08-15       Impact factor: 7.217

Review 5.  Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Authors:  Cindy Strehl; Lisa Ehlers; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 6.  Neural immune pathways and their connection to inflammatory diseases.

Authors:  Farideh Eskandari; Jeanette I Webster; Esther M Sternberg
Journal:  Arthritis Res Ther       Date:  2003-09-23       Impact factor: 5.156

7.  Use of the dexamethasone-corticotrophin releasing hormone test to assess hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis.

Authors:  Eman A Hasan; David S Jessop; Lynsey L Power; Paul T Monk; John R Kirwan
Journal:  Int J Endocrinol       Date:  2009-09-29       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.